Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15483478 | 0.84 | LMNA (0.51) | SMN1; SMN2HPGDL3MBTL1LMNARAB9A | |
| SCHEMBL14509583 | 0.80 | ALDH1A1 (0.58) | SMN1; SMN2HPGDL3MBTL1CCNE2CCNE1 | |
| SCHEMBL8141768 | 0.79 | PTGS1 (0.43) | SMN1; SMN2HPGDL3MBTL1LMNARAB9A | |
| SCHEMBL8138335 | 0.78 | PDE3B (0.54) | SMN1; SMN2HPGDL3MBTL1LMNARAB9A | |
| SCHEMBL15483491 | 0.78 | HPGD (0.44) | SMN1; SMN2HPGDL3MBTL1LMNARAB9A | |
| SCHEMBL8149547 | 0.77 | ACHE (0.47) | SMN1; SMN2HPGDL3MBTL1LMNARAB9A | |
| SCHEMBL8145986 | 0.77 | NPSR1 (0.48) | SMN1; SMN2HPGDL3MBTL1LMNARAB9A | |
| SCHEMBL13975120 | 0.75 | PPM1A (0.44) | SMN1; SMN2LMNARAB9AMEN1KMT2A | |
| SCHEMBL25746206 | 0.74 | HPGD (0.51) | SMN1; SMN2HPGDL3MBTL1LMNACCNE2 | |
| SCHEMBL31283944 | 0.74 | HPGD (0.51) | SMN1; SMN2HPGDL3MBTL1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | SMN1; SMN2 1564/4885HPGD 3745/4885L3MBTL1 2200/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SMN1; SMN2 1564/4885HPGD 3745/4885L3MBTL1 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.